PolyPid
Petah Tikva, Israel· Est.
PolyPid delivers precision, long‑acting drug depots via its Kynatrix™ platform to improve outcomes in surgery, metabolism and cancer.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
PolyPid delivers precision, long‑acting drug depots via its Kynatrix™ platform to improve outcomes in surgery, metabolism and cancer.
Surgical CareMetabolic DiseaseOncology
Technology Platform
Kynatrix™ is a proprietary matrix that provides zero‑burst, customizable-duration release of diverse APIs directly at the site of care, enabling high local concentrations with minimal systemic exposure.
Opportunities
Regulatory approval of D‑PLEX 100 opens a large surgical prophylaxis market and validates the Kynatrix™ platform for rapid expansion into metabolic and oncology indications.
Risk Factors
Key risks include regulatory delays, competition from systemic antibiotics and alternative local delivery technologies, and challenges scaling manufacturing for commercial launch.
Competitive Landscape
Competing SSI prophylactics rely on systemic antibiotics or coated sutures; PolyPid’s localized, long‑acting matrix offers superior site‑specific exposure and reduced systemic toxicity, differentiating it in the market.